Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
1,825,471
-
Shares change
-
+484,890
-
Total reported value, excl. options
-
$3,943,571
-
Value change
-
+$1,072,822
-
Put/Call ratio
-
1.86%
-
Number of buys
-
18
-
Number of sells
-
-5
-
Price
-
$2.16
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q4 2024
31 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q4 2024.
Gain Therapeutics, Inc. - COM (GANX) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,825,471 shares
.
Largest 10 shareholders include DME Capital Management, LP (566,130 shares), GEODE CAPITAL MANAGEMENT, LLC (267,421 shares), VANGUARD GROUP INC (177,075 shares), JONES FINANCIAL COMPANIES LLLP (98,250 shares), MARSHALL WACE, LLP (91,738 shares), MORGAN STANLEY (88,512 shares), BlackRock, Inc. (86,061 shares), NORTHERN TRUST CORP (84,586 shares), STATE STREET CORP (71,137 shares), and Cambridge Investment Research Advisors, Inc. (54,500 shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.